COVID-19 was caused by a novel coronavirus known as SARS-CoV-2. The COVID-19
disease outbreak has been avowed as a global pandemic by the World Health Organization at …

… alternative drug against SARS-CoV-2 virus with minimum side effects. Though our in silico
studies of these compounds are showing a promising results against SARS-CoV-2 main …

… leads for possible inhibitors of the SARS-CoV-2 ADP Ribose … In silico screening has proven
to be a highly effective, … with therapeutic effectiveness against SARS-CoV-2 ARP enzyme. …

… investigated for their probable effect against SARS-CoV-2 using in silico techniques [39]. …
from several databases were applied in silico against SARS-CoV PL pro and 3CL pro inhibition…

… activity against SARS coronavirus 3C-like protease [36] and anti-HBV (hepatitis B virus)
activity [37]. … SARS-coronavirus, influenza, foot-and-mouth disease, human immunodeficiency …

… structure-based drug designs using SARS-CoV-2 crystalline protein structures available …
SARS-CoV-2 infection is to inhibit the activity of S-glycoprotein, as it restricts the latching of virus …

… Plants and their phytoconstituents that have been reported to be active against SARS CoV in
… A: Evaluation of effect on the replication of HSV using in vitro and in silico approaches; MTT …

… In silico studies have shown that 17 binds with high affinity to … by SARS-CoV-2 to cause
COVID-19 (Fig. 6), suggesting that this compound could be a potential inhibitor of coronavirus …

… SARS-CoV-2 and SARS-CoV. Therefore, the methodologies employed earlier to disrupt the
binding of MERS or SARS-CoV … in silico as possible inhibitors of the major protease of SARS-…

… bioprospecting and molecular docking as alternative tools for the search of efficient compounds
to combat COVID-19 [7,11,12,13]. The in silico … In silico techniques achieve success in …